cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8319071
title: Additional file 6: of Some data quality issues at ClinicalTrials.gov

description: Records with a completion date. The data (64,496 records from Additional file 5: Table S3) were sorted into a “ComplDate” sheet for trials with completion dates, with the remaining records in a “ComplDate_leftovers” sheet. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (5471 selected records with 1271 leftovers), (2) Completed (38,997; 2454), (3) Enrolling by invitation (341; 45), (4) Recruiting (7833; 1546), (5) Suspended (233; 106), and (6) Terminated (5810; 389). The sheets for these categories are numbered 1–6, respectively. The file is available at https://osf.io/jcb92 . (ODS 2300 kb)
DOI: 10.6084/m9.figshare.8319071.v1
title: Additional file 6: of Some data quality issues at ClinicalTrials.gov

description: Records with a completion date. The data (64,496 records from Additional file 5: Table S3) were sorted into a “ComplDate” sheet for trials with completion dates, with the remaining records in a “ComplDate_leftovers” sheet. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (5471 selected records with 1271 leftovers), (2) Completed (38,997; 2454), (3) Enrolling by invitation (341; 45), (4) Recruiting (7833; 1546), (5) Suspended (233; 106), and (6) Terminated (5810; 389). The sheets for these categories are numbered 1–6, respectively. The file is available at https://osf.io/jcb92 . (ODS 2300 kb)
DOI: 10.6084/m9.figshare.8319062
title: Additional file 5: of Some data quality issues at ClinicalTrials.gov

description: Records of drugs or biologicals. Records with “drug:”, “biological: ”, or both of these words in the “intervention” field are listed in a “Drugs+Bio” sheet, with the remaining in a “Drugs+Bio_leftovers” sheet. The data (79,838 records from Additional file 4: Table S2) are presented in the following six Recruitment Type categories: (1) Active, not recruiting (6742 selected records with 1840 leftovers), (2) Completed (41,451; 8561), (3) Enrolling by invitation (386; 220), (4) Recruiting (9379; 3612), (5) Suspended (339; 93), and (6) Terminated (6199; 1016). The sheets for these categories are numbered 1–6, respectively. The file is available at https://osf.io/jcb92 . (ODS 2830 kb)
DOI: 10.6084/m9.figshare.8319056
title: Additional file 17: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: 165 LCLs used for RNA-Seq analysis and their parents. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.8319059
title: Additional file 18: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: 131 whole blood samples used for RNA-Seq analysis. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.8319056.v1
title: Additional file 17: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: 165 LCLs used for RNA-Seq analysis and their parents. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.8319062.v1
title: Additional file 5: of Some data quality issues at ClinicalTrials.gov

description: Records of drugs or biologicals. Records with “drug:”, “biological: ”, or both of these words in the “intervention” field are listed in a “Drugs+Bio” sheet, with the remaining in a “Drugs+Bio_leftovers” sheet. The data (79,838 records from Additional file 4: Table S2) are presented in the following six Recruitment Type categories: (1) Active, not recruiting (6742 selected records with 1840 leftovers), (2) Completed (41,451; 8561), (3) Enrolling by invitation (386; 220), (4) Recruiting (9379; 3612), (5) Suspended (339; 93), and (6) Terminated (6199; 1016). The sheets for these categories are numbered 1–6, respectively. The file is available at https://osf.io/jcb92 . (ODS 2830 kb)
DOI: 10.6084/m9.figshare.8319053
title: Additional file 4: of Some data quality issues at ClinicalTrials.gov

description: Records selected for their start dates. Records having a “Start date” from 1 January 2005 to 31 Deccember 2014 (both inclusive) are listed in a “StartDate” sheet, with the remaining records in a “StartDate_leftovers” sheet. The data (112,013 records from Additional file 3: Table S1) are presented in the following six Recruitment Type categories: (1) Active, not recruiting (8582 selected records, with 2512 leftovers), (2) Completed (50,012; 17,282), (3) Enrolling by invitation (606; 416), (4) Recruiting (12,991; 10,232), (5) Suspended (432; 165), and (6) Terminated (7215, 1568). The sheets are numbered 1–6, respectively. The file is available at https://osf.io/jcb92 . (ODS 3850 kb)
DOI: 10.6084/m9.figshare.8319059.v1
title: Additional file 18: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: 131 whole blood samples used for RNA-Seq analysis. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.8319053.v1
title: Additional file 4: of Some data quality issues at ClinicalTrials.gov

description: Records selected for their start dates. Records having a “Start date” from 1 January 2005 to 31 Deccember 2014 (both inclusive) are listed in a “StartDate” sheet, with the remaining records in a “StartDate_leftovers” sheet. The data (112,013 records from Additional file 3: Table S1) are presented in the following six Recruitment Type categories: (1) Active, not recruiting (8582 selected records, with 2512 leftovers), (2) Completed (50,012; 17,282), (3) Enrolling by invitation (606; 416), (4) Recruiting (12,991; 10,232), (5) Suspended (432; 165), and (6) Terminated (7215, 1568). The sheets are numbered 1–6, respectively. The file is available at https://osf.io/jcb92 . (ODS 3850 kb)
DOI: 10.6084/m9.figshare.8319038
title: Additional file 13: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: All 25â kb windows with significant p values from sliding window analysis. (XLSX 478 kb)
DOI: 10.6084/m9.figshare.8319038.v1
title: Additional file 13: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: All 25â kb windows with significant p values from sliding window analysis. (XLSX 478 kb)
DOI: 10.6084/m9.figshare.8319023
title: Additional file 10: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: Location of closest imprinted differentially methylated region from two published studies to each imprinted gene identified in our dataset. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.8319023.v1
title: Additional file 10: of RNA-Seq in 296 phased trios provides a high-resolution map of genomic imprinting

description: Location of closest imprinted differentially methylated region from two published studies to each imprinted gene identified in our dataset. (XLSX 17 kb)
DOI: 10.6084/m9.figshare.8319008
title: Additional file 3: of Some data quality issues at ClinicalTrials.gov

description: Data (112,013 records) comprises a spliced version of the 26 fields in tsv format and one field obtained from the XML files. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (11,094 records), (2) Completed (67,294), (3) Enrolling by invitation (1022), (4) Recruiting (23,223), (5) Suspended (597), and (6) Terminated (8783). The sheets are numbered 1â€“6, respectively. The file is available at https://osf.io/jcb92 . (ZIP 4860 kb)
DOI: 10.6084/m9.figshare.8319008.v1
title: Additional file 3: of Some data quality issues at ClinicalTrials.gov

description: Data (112,013 records) comprises a spliced version of the 26 fields in tsv format and one field obtained from the XML files. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (11,094 records), (2) Completed (67,294), (3) Enrolling by invitation (1022), (4) Recruiting (23,223), (5) Suspended (597), and (6) Terminated (8783). The sheets are numbered 1â€“6, respectively. The file is available at https://osf.io/jcb92 . (ZIP 4860 kb)
DOI: 10.6084/m9.figshare.8318996
title: Additional file 20: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 4. (XLSX 553 kb)
DOI: 10.6084/m9.figshare.8318999
title: Additional file 21: of Some data quality issues at ClinicalTrials.gov

description: Whether PI information is available from Responsible Party. (XLSX 1495 kb)
DOI: 10.6084/m9.figshare.8319002
title: Additional file 2: of Some data quality issues at ClinicalTrials.gov

description: S1. Folder: The scripts used to process particular steps.Â The folder is available at https://osf.io/jcb92 . (ZIP 10 kb)
DOI: 10.6084/m9.figshare.8318999.v1
title: Additional file 21: of Some data quality issues at ClinicalTrials.gov

description: Whether PI information is available from Responsible Party. (XLSX 1495 kb)
DOI: 10.6084/m9.figshare.8319002.v1
title: Additional file 2: of Some data quality issues at ClinicalTrials.gov

description: S1. Folder: The scripts used to process particular steps.Â The folder is available at https://osf.io/jcb92 . (ZIP 10 kb)
DOI: 10.6084/m9.figshare.8318996.v1
title: Additional file 20: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 4. (XLSX 553 kb)
DOI: 10.6084/m9.figshare.8318987
title: Additional file 19: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 3. (XLSX 2105 kb)
DOI: 10.6084/m9.figshare.8318981
title: Additional file 18: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 2. (XLSX 1406 kb)
DOI: 10.6084/m9.figshare.8318987.v1
title: Additional file 19: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 3. (XLSX 2105 kb)
DOI: 10.6084/m9.figshare.8318975
title: Additional file 17: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 1. (XLSX 3330 kb)
DOI: 10.6084/m9.figshare.8318981.v1
title: Additional file 18: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 2. (XLSX 1406 kb)
DOI: 10.6084/m9.figshare.8318969
title: Additional file 16: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguities. An overview of Additional file 17: Table S15 to Additional file 20: Table S18. (ODS 22 kb)
DOI: 10.6084/m9.figshare.8318975.v1
title: Additional file 17: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguitiesâ€”step 1. (XLSX 3330 kb)
DOI: 10.6084/m9.figshare.8318960
title: Additional file 15: of Some data quality issues at ClinicalTrials.gov

description: PIs in the history records of a sample of Additional file 10: Table S8 rejects and Additional file 13: Table S11 rejects. (ODS 219 kb)
DOI: 10.6084/m9.figshare.8318969.v1
title: Additional file 16: of Some data quality issues at ClinicalTrials.gov

description: Processing of PI names to identify ambiguities. An overview of Additional file 17: Table S15 to Additional file 20: Table S18. (ODS 22 kb)
DOI: 10.6084/m9.figshare.8318960.v1
title: Additional file 15: of Some data quality issues at ClinicalTrials.gov

description: PIs in the history records of a sample of Additional file 10: Table S8 rejects and Additional file 13: Table S11 rejects. (ODS 219 kb)
DOI: 10.6084/m9.figshare.8318948
title: Additional file 14: of Some data quality issues at ClinicalTrials.gov

description: The 10,572 rejected rows in Additional file 13: Table S11 came from 8907 unique NCT IDs. (ODS 203 kb)
DOI: 10.6084/m9.figshare.8318942
title: Additional file 13: of Some data quality issues at ClinicalTrials.gov

description: Data with real persons. The data (71,359 records from Additional file 12: Table S10) were sorted into a “Person” sheet with the records that had the names of real people in the “Last name” field, and a “NonPerson” sheet with the remaining junk records. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4112 selected records with 693 leftovers), (2) Completed (17,081; 7054), (3) Enrolling by invitation (190; 11), (4) Recruiting (35,447; 1801), (5) Suspended (206; 8), and (6) Terminated (3751; 1005). The sheets for these categories are numbered 1–6, respectively. (XLS 5690 kb)
DOI: 10.6084/m9.figshare.8318948.v1
title: Additional file 14: of Some data quality issues at ClinicalTrials.gov

description: The 10,572 rejected rows in Additional file 13: Table S11 came from 8907 unique NCT IDs. (ODS 203 kb)
DOI: 10.6084/m9.figshare.8318942.v1
title: Additional file 13: of Some data quality issues at ClinicalTrials.gov

description: Data with real persons. The data (71,359 records from Additional file 12: Table S10) were sorted into a “Person” sheet with the records that had the names of real people in the “Last name” field, and a “NonPerson” sheet with the remaining junk records. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4112 selected records with 693 leftovers), (2) Completed (17,081; 7054), (3) Enrolling by invitation (190; 11), (4) Recruiting (35,447; 1801), (5) Suspended (206; 8), and (6) Terminated (3751; 1005). The sheets for these categories are numbered 1–6, respectively. (XLS 5690 kb)
DOI: 10.6084/m9.figshare.8318933
title: Additional file 12: of Some data quality issues at ClinicalTrials.gov

description: Data in the form of individual investigators and their matching roles. The data (31,375 records from Additional file 11: Table S9) were sorted into a “LineByLine” sheet, where records that contained multiple names and roles were segregated such that each row contains one name and the corresponding role. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4805 records), (2) Completed (24,135), (3) Enrolling by invitation (201), (4) Recruiting (37,248), (5) Suspended (214), and (6) Terminated (4756). The sheets for these categories are numbered 1–6, respectively. (XLS 5686 kb)
DOI: 10.6084/m9.figshare.8318933.v1
title: Additional file 12: of Some data quality issues at ClinicalTrials.gov

description: Data in the form of individual investigators and their matching roles. The data (31,375 records from Additional file 11: Table S9) were sorted into a “LineByLine” sheet, where records that contained multiple names and roles were segregated such that each row contains one name and the corresponding role. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4805 records), (2) Completed (24,135), (3) Enrolling by invitation (201), (4) Recruiting (37,248), (5) Suspended (214), and (6) Terminated (4756). The sheets for these categories are numbered 1–6, respectively. (XLS 5686 kb)
DOI: 10.6084/m9.figshare.8318921
title: Additional file 11: of Some data quality issues at ClinicalTrials.gov

description: Records that list matching numbers of names and roles of the investigators. The data (31,392 records from Additional file 10: Table S8) were sorted into the “MatchedPipes” sheet, where the number of pipes (each one of which delineates one name or role) was the same in the name and corresponding role cells, and an “UnmatchedPipes” sheet with the remaining records. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4051 selected records with 1 leftover), (2) Completed (19,392; 12), (3) Enrolling by invitation (162; 0), (4) Recruiting (3782; 2), (5) Suspended (181; 1), and (6) Terminated (3807; 1). The sheets for these categories are numbered 1–6, respectively. (XLS 6429 kb)
DOI: 10.6084/m9.figshare.8318921.v1
title: Additional file 11: of Some data quality issues at ClinicalTrials.gov

description: Records that list matching numbers of names and roles of the investigators. The data (31,392 records from Additional file 10: Table S8) were sorted into the “MatchedPipes” sheet, where the number of pipes (each one of which delineates one name or role) was the same in the name and corresponding role cells, and an “UnmatchedPipes” sheet with the remaining records. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4051 selected records with 1 leftover), (2) Completed (19,392; 12), (3) Enrolling by invitation (162; 0), (4) Recruiting (3782; 2), (5) Suspended (181; 1), and (6) Terminated (3807; 1). The sheets for these categories are numbered 1–6, respectively. (XLS 6429 kb)
DOI: 10.6084/m9.figshare.8318909
title: Additional file 10: of Some data quality issues at ClinicalTrials.gov

description: Records that list both the name and the role of the investigator. The names of the investigators and their corresponding roles were extracted from Additional file 8: Table S6 (31,833 records) and Additional file 9: Table S7 (3288 records). They were sorted into a “NameAndRole” sheet for trials that listed both the name and role of the investigator, and a “Nulls” sheet that listed the remaining records. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4052 selected records with 383 leftovers), (2) Completed (19,404; 2726), (3) Enrolling by invitation (162; 23), (4) Recruiting (3784; 156), (5) Suspended (182; 11), and (6) Terminated (3808; 430). The sheets for these categories are numbered 1–6, respectively. (XLS 6779 kb)
DOI: 10.6084/m9.figshare.8318909.v1
title: Additional file 10: of Some data quality issues at ClinicalTrials.gov

description: Records that list both the name and the role of the investigator. The names of the investigators and their corresponding roles were extracted from Additional file 8: Table S6 (31,833 records) and Additional file 9: Table S7 (3288 records). They were sorted into a “NameAndRole” sheet for trials that listed both the name and role of the investigator, and a “Nulls” sheet that listed the remaining records. The data are presented in the following six Recruitment Type categories: (1) Active, not recruiting (4052 selected records with 383 leftovers), (2) Completed (19,404; 2726), (3) Enrolling by invitation (162; 23), (4) Recruiting (3784; 156), (5) Suspended (182; 11), and (6) Terminated (3808; 430). The sheets for these categories are numbered 1–6, respectively. (XLS 6779 kb)
DOI: 10.6084/m9.figshare.8318891
title: Additional file 3: of Uncertainty about flying conspecifics causes territorial contests of the Old World swallowtail, Papilio machaon

description: Data of response phase / duration (s) to each specimen. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.8318891.v1
title: Additional file 3: of Uncertainty about flying conspecifics causes territorial contests of the Old World swallowtail, Papilio machaon

description: Data of response phase / duration (s) to each specimen. (XLSX 10 kb)
DOI: 10.6084/m9.figshare.8318879
title: Additional file 11: of Stationary phase persister formation in Escherichia coli can be suppressed by piperacillin and PBP3 inhibition

description: Supplemental Methods. (ZIP 423 kb)
DOI: 10.6084/m9.figshare.8318879.v1
title: Additional file 11: of Stationary phase persister formation in Escherichia coli can be suppressed by piperacillin and PBP3 inhibition

description: Supplemental Methods. (ZIP 423 kb)
DOI: 10.6084/m9.figshare.8318861
title: Additional file 1: of Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs

description: Data S1. Mutations in the library (CSV 51 kb)
DOI: 10.6084/m9.figshare.8318861.v1
title: Additional file 1: of Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs

description: Data S1. Mutations in the library (CSV 51 kb)
DOI: 10.6084/m9.figshare.8318768
title: Additional file 1: of RNA-Seq analysis of gene expression changes triggered by Xanthomonas oryzae pv. oryzae in a susceptible rice genotype

description: Table S1. Summary of RNA-Seq paired-end data produced by Illumina sequencing. Table S2. List of 1143 DEGs expressed at different time points in JG30 genotype after infection of PXO99A and PH strains. The significant DEGs were retrieved by Log2FC ≥1 (up-regulated genes) or ≤ − 1 (down-regulated genes) as a threshold level. The gene ID, FPKM based expression pattern, GO terms, and chromosomal position are mentioned in the table. Table S3. A detailed list of TFs expressed differentially in JG30 genotype at different time points after PXO99A and PH inoculation. Table S4. List of significant enriched different Kinase responsive genes differentially expressed at different time points in JG30 genotype after PXO99A and PH strains. Table S5. A detailed list of differentially expressed peroxidase responsive genes in JG30 genotype after PXO99A and PH inoculations at different time points. Table S6. Significant KEGG pathways (P-value ≤0.05) involved in JG30 genotype after PXO99A and PH infection. Table S7. MapMan analysis of DEGs involved in biotic stress pathway in JG30 genotype. The gene ID, bin code, gene description, and average Log2FC values are presented in the below-mentioned table. Table S8. MapMan analysis of DEGs involved in different metabolic pathways in JG30 genotype. The gene ID, bin code, gene description, and average Log2FC values are presented in the below-mentioned table. Table S9. Summary of GO terms enriched in JG30 genotype after PXO99A and PH infection. Table S10. A list of significantly enriched GO terms (P-value ≤0.05) having DEGs at different time points after infection of PXO99A and PH strains. Table S11. A list of eight genes primers used for RNA-Seq data validation. (XLSX 359 kb)
DOI: 10.6084/m9.figshare.8318768.v1
title: Additional file 1: of RNA-Seq analysis of gene expression changes triggered by Xanthomonas oryzae pv. oryzae in a susceptible rice genotype

description: Table S1. Summary of RNA-Seq paired-end data produced by Illumina sequencing. Table S2. List of 1143 DEGs expressed at different time points in JG30 genotype after infection of PXO99A and PH strains. The significant DEGs were retrieved by Log2FC ≥1 (up-regulated genes) or ≤ − 1 (down-regulated genes) as a threshold level. The gene ID, FPKM based expression pattern, GO terms, and chromosomal position are mentioned in the table. Table S3. A detailed list of TFs expressed differentially in JG30 genotype at different time points after PXO99A and PH inoculation. Table S4. List of significant enriched different Kinase responsive genes differentially expressed at different time points in JG30 genotype after PXO99A and PH strains. Table S5. A detailed list of differentially expressed peroxidase responsive genes in JG30 genotype after PXO99A and PH inoculations at different time points. Table S6. Significant KEGG pathways (P-value ≤0.05) involved in JG30 genotype after PXO99A and PH infection. Table S7. MapMan analysis of DEGs involved in biotic stress pathway in JG30 genotype. The gene ID, bin code, gene description, and average Log2FC values are presented in the below-mentioned table. Table S8. MapMan analysis of DEGs involved in different metabolic pathways in JG30 genotype. The gene ID, bin code, gene description, and average Log2FC values are presented in the below-mentioned table. Table S9. Summary of GO terms enriched in JG30 genotype after PXO99A and PH infection. Table S10. A list of significantly enriched GO terms (P-value ≤0.05) having DEGs at different time points after infection of PXO99A and PH strains. Table S11. A list of eight genes primers used for RNA-Seq data validation. (XLSX 359 kb)
DOI: 10.6084/m9.figshare.8318747
title: Additional file 6: of About the existence of common determinants of gene expression in the porcine liver and skeletal muscle

description: Table S6. Sequences of the primers used to validate CNVRs by qPCR. (XLSX 9 kb)